Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
NCT06177171 is a phase 1 interventional trial sponsored by Varun Monga, MBBS. As of 21 Nov 2026, it is active and no longer recruiting. It studies ASTX727 and Olaparib in ATM Gene Mutation, BRCA Mutation and 4 more conditions. The registry lists an enrollment of 13 participants at 1 site in 1 country. The registry lists a start date of 7 Feb 2024 and a primary completion date of 31 Jan 2028. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06177171 |
| Status | Active not recruiting |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Varun Monga, MBBS |
| Enrollment | 13 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | ATM Gene Mutation, BRCA Mutation, BRCA1 Mutation, BRCA2 Mutation, Checkpoint Kinase 2 Gene Mutation and PALB2 Gene Mutation |
| Drugs | ASTX727 and Olaparib |
| Start | 7 Feb 2024 |
| Primary completion | 31 Jan 2028 |
| Study completion | 31 Jan 2028 |
| Last update posted | 20 Oct 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California, San Francisco
San Francisco
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06177171
Each answer restates registry values shown on this page.
What is NCT06177171?
NCT06177171 is a phase 1 interventional trial sponsored by Varun Monga, MBBS. It studies ASTX727 and Olaparib in ATM Gene Mutation, BRCA Mutation and 4 more conditions.
Is NCT06177171 recruiting?
As of 21 Nov 2026, it is active and no longer recruiting.
Who leads NCT06177171?
The registry names Varun Monga, MBBS (principal investigator, University of California, San Francisco) as the overall official.
Where does NCT06177171 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT06177171 study?
The registered drug and biological interventions are ASTX727 and Olaparib.
When is NCT06177171 expected to complete?
The registry lists a primary completion date of 31 Jan 2028 and a study completion date of 31 Jan 2028. The sponsor last updated the record on 20 Oct 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.